Breaking News

Friday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Recommendations	BTIG sees Legend commercializing Carvykti in earlier lines after study hits goal » 11:56 01/27/23 01/27 11:56 01/27/23 11:56 LEGN Legend Biotech $53.12 / -0.75 (-1.39%) , JNJ Johnson & Johnson $168.69 / -0.16 (-0.09%) After Legend Biotech… After Legend Biotech (LEGN) and partner Johnson and Johnson (JNJ) announced that CARTITUDE-4, the Phase 3 study evaluating Carvykti for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint, BTIG analyst Justin Zelin said the firm views this "highly anticipated readout" of the study "positively" and expects that Legend and J&J will commercialize Carvykti in earlier lines of therapy. The firm, which sees the news as a confirmatory event that supports Carvykti use in earlier lines against active standard of care comparator in "a robust phase 3 study," thinks this could "cement" a position as "a best-in-class autologous BCMA CAR-T therapy" in multiple myeloma. BTIG has a Buy rating and $75 price target on Legend shares. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options LEGN JNJ LEGN Legend Biotech $53.12 / -0.75 (-1.39%) 01/27/23 Legend Biotech says Carvykti myeloma study met primary endpoint 01/02/23 Legend says China accepts ciltacabtagene New Drug Application 11/21/22 FDA clears Legend Biotech's IND application for LB2102 to treat extensive NSLC 11/03/22 Legend Biotech announces seven studies accepted for presentation at ASH JNJ Johnson & Johnson $168.69 / -0.16 (-0.09%) 01/27/23 Janssen announces unblinding of Phase 3 CARTITUDE-4 study of CARVYKTI 01/24/23 Johnson & Johnson says assuming a lot of inflationary carryover in 2023 01/24/23 Johnson & Johnson sees 'above market growth' in Pharmaceutical segment in FY23 01/24/23 Johnson & Johnson expects FY23 OPEX leverage offset by inflationary pressures LEGN JNJ LEGN Legend Biotech $53.12 / -0.75 (-1.39%) 01/27/23 Piper Sandler Piper keeps $78 target on Legend Biotech after Carvykti trial hits 01/25/23 Barclays Legend Biotech price target raised to $65 from $53 at Barclays 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 12/20/22 Piper Sandler Piper Sandler names three top biotechnology picks for 2023 JNJ Johnson & Johnson $168.69 / -0.16 (-0.09%) 01/25/23 JMP Securities J&J conference call comments 'a good sign' for Protagonist, says JMP Securities 01/24/23 H.C. Wainwright Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright 01/18/23 SVB Securities Moderna price target raised to $111 from $102 at SVB Securities JNJ JNJ Johnson & Johnson $168.69 / -0.16 (-0.09%) 01/24/23 Johnson & Johnson sees FY23 adjusted EPS $10.45- $10.65, consensus $10.33 01/24/23 Johnson & Johnson sees FY23 adjusted operational EPS $10.40-$10.60 01/24/23 Johnson & Johnson sees FY23 adjusted operation EPS $10.50, consensus $10.33 01/24/23 Johnson & Johnson reports Q4 adjusted EPS $2.35, consensus $2.23 27 Jul JNJ JNJ Johnson & Johnson $168.69 / -0.16 (-0.09%) 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/09/23 J&J may look for deals that boost eye care, surgical robots units, Reuters says 12/04/22 J&J says won't make offer for Horizon Therapeutics, Bloomberg reports 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says LEGN JNJ LEGN Legend Biotech $53.12 / -0.75 (-1.39%) 11/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations JNJ Johnson & Johnson $168.69 / -0.16 (-0.09%) 01/24/23 What You Missed On Wall Street On Tuesday 01/24/23 What You Missed On Wall Street This Morning 01/24/23 Fly Intel: Pre-market Movers 01/07/23 Short Report: Bad News Bears continue to claw Silvergate, Futu Holdings 03/09/23 Biopharma/Biotech JNJ JNJ Johnson & Johnson $168.69 / -0.16 (-0.09%) 01/24/23 Unusually active option classes on open January 24th 01/20/23 Johnson & Johnson put buyer realizes 33% same-day gains 01/11/23 Unusually active option classes on open January 11th 12/22/22 Johnson & Johnson put volume heavy and directionally bearish
Recommendations	Piper keeps $78 target on Legend Biotech after Carvykti trial hits » 10:49 01/27/23 01/27 10:49 01/27/23 10:49 LEGN Legend Biotech / + , JNJ Johnson & Johnson $168.29 / -0.56 (-0.33%) Piper Sandler analyst… Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Legend Biotech (LEGN) with a $78 price target after the company announced that CARTITUDE-4, the Phase 3 study evaluating Carvykti for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint. The analyst anticipates Legend and Johnson & Johnson's Janssen will report data at the American Society of Clinical Oncology meeting in June and file a supplemental Biologics License Application which could expand Carvykti's label into earlier lines of therapy. Piper continues to forecast Carvykti growth of 157% to $344M in 2023. It notes that Janssen projects peak Carvykti sales of $5B. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options LEGN JNJ LEGN Legend Biotech / + 01/27/23 Legend Biotech says Carvykti myeloma study met primary endpoint 01/02/23 Legend says China accepts ciltacabtagene New Drug Application 11/21/22 FDA clears Legend Biotech's IND application for LB2102 to treat extensive NSLC 11/03/22 Legend Biotech announces seven studies accepted for presentation at ASH JNJ Johnson & Johnson $168.29 / -0.56 (-0.33%) 01/27/23 Janssen announces unblinding of Phase 3 CARTITUDE-4 study of CARVYKTI 01/24/23 Johnson & Johnson says assuming a lot of inflationary carryover in 2023 01/24/23 Johnson & Johnson sees 'above market growth' in Pharmaceutical segment in FY23 01/24/23 Johnson & Johnson expects FY23 OPEX leverage offset by inflationary pressures LEGN JNJ LEGN Legend Biotech / + 01/25/23 Barclays Legend Biotech price target raised to $65 from $53 at Barclays 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 12/20/22 Piper Sandler Piper Sandler names three top biotechnology picks for 2023 12/20/22 Piper Sandler Piper Sandler ups Legend Biotech target, names top 2023 pick JNJ Johnson & Johnson $168.29 / -0.56 (-0.33%) 01/25/23 JMP Securities J&J conference call comments 'a good sign' for Protagonist, says JMP Securities 01/24/23 H.C. Wainwright Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright 01/18/23 SVB Securities Moderna price target raised to $111 from $102 at SVB Securities 01/06/23 BofA Fate Therapeutics double downgraded to Underperform at BofA JNJ JNJ Johnson & Johnson $168.29 / -0.56 (-0.33%) 01/24/23 Johnson & Johnson sees FY23 adjusted EPS $10.45- $10.65, consensus $10.33 01/24/23 Johnson & Johnson sees FY23 adjusted operational EPS $10.40-$10.60 01/24/23 Johnson & Johnson sees FY23 adjusted operation EPS $10.50, consensus $10.33 01/24/23 Johnson & Johnson reports Q4 adjusted EPS $2.35, consensus $2.23 27 Jul JNJ JNJ Johnson & Johnson $168.29 / -0.56 (-0.33%) 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/09/23 J&J may look for deals that boost eye care, surgical robots units, Reuters says 12/04/22 J&J says won't make offer for Horizon Therapeutics, Bloomberg reports 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says LEGN JNJ LEGN Legend Biotech / + 11/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations JNJ Johnson & Johnson $168.29 / -0.56 (-0.33%) 01/24/23 What You Missed On Wall Street On Tuesday 01/24/23 What You Missed On Wall Street This Morning 01/24/23 Fly Intel: Pre-market Movers 01/07/23 Short Report: Bad News Bears continue to claw Silvergate, Futu Holdings 03/09/23 Biopharma/Biotech JNJ JNJ Johnson & Johnson $168.29 / -0.56 (-0.33%) 01/24/23 Unusually active option classes on open January 24th 01/20/23 Johnson & Johnson put buyer realizes 33% same-day gains 01/11/23 Unusually active option classes on open January 11th 12/22/22 Johnson & Johnson put volume heavy and directionally bearish
Hot Stocks	Spark Therapeutics enters collaboration with Neurochase » 09:02 01/27/23 01/27 09:02 01/27/23 09:02 RHHBY Roche $39.38 / -0.67 (-1.67%) Spark Therapeutics… Spark Therapeutics announced a strategic collaboration to develop Neurochase's proprietary delivery technology for use with selected gene therapies for rare diseases in CNS. Through this collaboration, Neurochase will bring their deep expertise in direct drug delivery technology to Spark's leading AAV platform. Neurochase is developing a proprietary drug delivery system and this collaboration enables Spark to develop selected gene therapies for CNS disorders using the Neurochase technology, which aims to improve targeted delivery of AAV gene therapy to neural structures using the method of Convection Enhanced Delivery. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $39.38 / -0.67 (-1.67%) 01/26/23 Roche launches COVID-19 PCR test to detect XBB.1.5 Omicron sub-variant 01/19/23 Roche says Phase 3 IMbrave050 study of Tecentriq-Avastin met primary endpoint 01/12/23 Roche announces EC approval of Xofluza in children aged one year and above 01/09/23 Sonnet BioTherapeutics, Roche collaborate for SON-1010 with atezolizumab RHHBY Roche $39.38 / -0.67 (-1.67%) 01/26/23 Citi Novartis downgraded to Neutral from Buy at Citi 01/24/23 Evercore ISI TG Therapeutics price target raised to $25 from $16 at Evercore ISI 01/18/23 Deutsche Bank Deutsche Bank bearish on Roche heading into FY23, cuts to Sell 01/18/23 Deutsche Bank Roche downgraded to Sell from Hold at Deutsche Bank RHHBY Roche $39.38 / -0.67 (-1.67%) 10/18/22 Roche reports nine months group sales CHF 47.04B vs. CHF 46.68B last year RHHBY Roche $39.38 / -0.67 (-1.67%) 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports RHHBY Roche $39.38 / -0.67 (-1.67%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today 01/30/23 Biopharma/Biotechs 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/02/23 Roche - RHHBY
Hot Stocks	Janssen announces unblinding of Phase 3 CARTITUDE-4 study of CARVYKTI » 08:37 01/27/23 01/27 08:37 01/27/23 08:37 JNJ Johnson & Johnson $168.84 / -0.66 (-0.39%) The Janssen… The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Committee recommended the unblinding of the study. "The CARTITUDE-4 study represents the first Phase 3 program in our comprehensive clinical development strategy for CARVYKTI, and further demonstrates our commitment to advance the treatment of patients with relapsed/refractory multiple myeloma," said Jordan Schecter, M.D., Vice President, Clinical Development Cellular Therapy Program, Janssen Research & Development, LLC. "We look forward to the presentation of the data from the CARTITUDE-4 study at a future medical meeting." ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $168.84 / -0.66 (-0.39%) 01/24/23 Johnson & Johnson says assuming a lot of inflationary carryover in 2023 01/24/23 Johnson & Johnson sees 'above market growth' in Pharmaceutical segment in FY23 01/24/23 Johnson & Johnson expects FY23 OPEX leverage offset by inflationary pressures 01/24/23 Johnson & Johnson says capital allocation strategy 'remains unchanged' JNJ Johnson & Johnson $168.84 / -0.66 (-0.39%) 01/25/23 JMP Securities J&J conference call comments 'a good sign' for Protagonist, says JMP Securities 01/24/23 H.C. Wainwright Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright 01/18/23 SVB Securities Moderna price target raised to $111 from $102 at SVB Securities 01/06/23 BofA Fate Therapeutics double downgraded to Underperform at BofA JNJ Johnson & Johnson $168.84 / -0.66 (-0.39%) 01/24/23 Johnson & Johnson sees FY23 adjusted EPS $10.45- $10.65, consensus $10.33 01/24/23 Johnson & Johnson sees FY23 adjusted operational EPS $10.40-$10.60 01/24/23 Johnson & Johnson sees FY23 adjusted operation EPS $10.50, consensus $10.33 01/24/23 Johnson & Johnson reports Q4 adjusted EPS $2.35, consensus $2.23 JNJ Johnson & Johnson $168.84 / -0.66 (-0.39%) 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/09/23 J&J may look for deals that boost eye care, surgical robots units, Reuters says 12/04/22 J&J says won't make offer for Horizon Therapeutics, Bloomberg reports 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says JNJ Johnson & Johnson $168.84 / -0.66 (-0.39%) 01/24/23 What You Missed On Wall Street On Tuesday 01/24/23 What You Missed On Wall Street This Morning 01/24/23 Fly Intel: Pre-market Movers 01/07/23 Short Report: Bad News Bears continue to claw Silvergate, Futu Holdings 03/09/23 Biopharma/Biotech JNJ Johnson & Johnson $168.84 / -0.66 (-0.39%) 01/24/23 Unusually active option classes on open January 24th 01/20/23 Johnson & Johnson put buyer realizes 33% same-day gains 01/11/23 Unusually active option classes on open January 11th 12/22/22 Johnson & Johnson put volume heavy and directionally bearish
Recommendations	JPMorgan sees Apellis rally with FDA action date fast approaching » 07:05 01/27/23 01/27 07:05 01/27/23 07:05 APLS Apellis $52.81 / +2.325 (+4.61%) JPMorgan analyst Anupam… JPMorgan analyst Anupam Rama says the February 26 FDA action date for Apellis Pharmaceuticals' pegcetacoplan in geographic atrophy is rapidly approaching. The firm anticipates approval of pegcetacoplan and a "best-in-class asset in the indication." On an approval, the analyst sees Apellis shares being valued in the low- to high- $80s share range versus downside to the $15-30/share range on a Complete Response Letter. It views a CRL as an "extremely low probability" scenario based on the totality of known data for pegcetacoplan. ShowHide Related Items >><< Company News Street Research Syndicate On The Fly Events Options APLS Apellis $52.81 / +2.325 (+4.61%) 01/09/23 Apellis expects 2022 Empaveli revenue of $65M 01/05/23 Apellis appoints Baumal as Chief Medical Officer 12/16/22 Apellis submits MAA to EMA for pegcetacoplan for geographic atrophy 11/18/22 Apellis announces FDA accepts NDA amendment, new PDUFA date for pegcetacoplan APLS Apellis $52.81 / +2.325 (+4.61%) 01/05/23 Citi Citi would buy Apellis on dip after talking to management about CMO change 01/03/23 Needham Vaxcyte named as Top Pick, added to Conviction list at Needham 01/03/23 Wells Fargo Wells Fargo downgrades Apellis to Equal Weight, lowers price target to $58 01/02/23 Wells Fargo Apellis downgraded to Equal Weight from Overweight at Wells Fargo 24 Mar APLS Apellis $52.81 / +2.325 (+4.61%) 01/06/23 Sell these stocks now, proven algorithm says 11/18/22 What You Missed On Wall Street On Friday 11/18/22 What You Missed On Wall Street This Morning 10/03/22 What You Missed On Wall Street On Monday 02/06/23 Biotech Ski Summit 02/26/23 PDUFA Date for Pegcetacoplan APLS Apellis $52.81 / +2.325 (+4.61%) 11/18/22 Unusually active option classes on open November 18th
Hot Stocks	Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent » 05:25 01/27/23 01/27 05:25 01/27/23 05:25 REGN Regeneron $741.32 / -0.06 (-0.01%) , SNY Sanofi $49.00 / +0.1 (+0.20%) Regeneron (REGN) and… Regeneron (REGN) and Sanofi (SNY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion for Dupixent, recommending expanded approval in the European Union, or EU, to treat severe atopic dermatitis in children six months to five years old who are candidates for systemic therapy. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. In June 2022, Dupixent was approved by the FDA for children in this age group. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNY REGN SNY Sanofi $49.00 / +0.1 (+0.20%) 01/25/23 Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial 01/25/23 Innate Pharma announces HSR clearance for Sanofi collaboration expansion 01/17/23 Sanofi selects THREAD as global decentralized clinical trials provider 01/12/23 California AG files suit against drugmakers, PBMs over insulin prices REGN Regeneron $741.32 / -0.06 (-0.01%) 01/06/23 2seventy Bio announces amendment to collaboration with Regeneron 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 Sensei announces clinical supply agreement with Regeneron for Libtayo 12/23/22 Regeneron: MHLW in Japan grants marketing, manufacturing approval for Libtayo REGN SNY REGN Regeneron $741.32 / -0.06 (-0.01%) 01/20/23 JPMorgan Regeneron upgraded to Overweight from Neutral at JPMorgan 01/09/23 Piper Sandler Piper 'at a loss' to explain Regeneron Q4 miss for Eylea 12/30/22 Oppenheimer Opco reveals three biotech stocks that will outperform in 2023 11/09/22 RBC Capital Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital SNY Sanofi $49.00 / +0.1 (+0.20%) 12/21/22 Barclays Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays 12/16/22 Goldman Sachs Sanofi reinstated with a Buy at Goldman Sachs 12/15/22 Guggenheim Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential 12/14/22 UBS Sanofi price target raised to EUR 97 from EUR 92 at UBS SNY REGN SNY Sanofi $49.00 / +0.1 (+0.20%) 10/28/22 Sanofi now sees 2022 business EPS growing 16% at CER 10/28/22 Sanofi reports Q3 business EPS EUR 2.88, up 17.9% at CER 07/28/22 Sanofi sees 2022 business EPS growing 15% at CER 07/28/22 Sanofi reports Q2 business EPS EUR 1.73, up 16.7% at CER REGN Regeneron $741.32 / -0.06 (-0.01%) 01/09/23 Regeneron sees about $1.5B in Q4 U.S. net product sales of Eylea 11/03/22 Regeneron reports Q3 EPS $11.14, consensus $9.48 11/02/22 Notable companies reporting before tomorrow's open SNY REGN SNY Sanofi $49.00 / +0.1 (+0.20%) 01/23/23 CytoReason to license IBD disease model to Sanofi 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says 12/21/22 Sanofi confirms to Bloomberg Zantac settlement in California REGN Regeneron $741.32 / -0.06 (-0.01%) 11/04/22 Supreme Court to hear Amgen appeal in Repatha patent dispute, Bloomberg says 09/16/22 WHO panel recommends against GSK, Regeneron COVID drugs, Bloomberg reports SNY REGN SNY Sanofi $49.00 / +0.1 (+0.20%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning 11/30/22 Fly Intel: Pre-market Movers REGN Regeneron $741.32 / -0.06 (-0.01%) 01/20/23 What You Missed On Wall Street On Friday 01/20/23 What You Missed On Wall Street This Morning 01/20/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/30/22 What You Missed On Wall Street This Morning 03/09/23 Biopharma/Biotech 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/24/23 Annual Meeting of AAAAI 2023 02/03/23 Sanofi - SNY 02/03/23 Regeneron - REGN 02/11/23 PDUFA Date for EYLEA (Aflibercept) Injection 02/28/23 PDUFA 03/30/23 PDUFA Date for Evkeeza (evinacumab) SNY REGN SNY Sanofi $49.00 / +0.1 (+0.20%) 11/11/22 Sanofi put volume heavy and directionally bearish 10/11/22 Sanofi put volume heavy and directionally bearish 09/26/22 Largest borrow rate increases among liquid names REGN Regeneron $741.32 / -0.06 (-0.01%) 09/16/22 Early notable gainers among liquid option names on September 16th 09/09/22 Early notable gainers among liquid option names on September 9th 09/08/22 Early notable gainers among liquid option names on September 8th 08/03/22 Early notable gainers among liquid option names on August 3rd

Thursday
Hot Stocks	Roche launches COVID-19 PCR test to detect XBB.1.5 Omicron sub-variant » 06:33 01/26/23 01/26 06:33 01/26/23 06:33 RHHBY Roche $40.05 / +0.1 (+0.25%) Roche and its subsidiary… Roche and its subsidiary TIB Molbiol announced they have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. "The XBB.1.5 variant is prevalent in the United States and is quickly spreading to other countries. Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment strategies. The test, VirSNiP SARS-CoV-2 Spike F486P, is for use on the LightCycler 480 II and cobas z 480," the company said. "Roche continues to develop timely diagnostic innovations related to COVID-19 by providing valuable insights - helping scientists and physicians understand this new strain, how it differs from other variants, and the impact it may have on public health," said Matt Sause, CEO of Roche Diagnostics. "Since the start of this global health crisis, Roche has been committed to bringing effective diagnostic solutions to address unmet needs to healthcare communities worldwide." ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $40.05 / +0.1 (+0.25%) 01/19/23 Roche says Phase 3 IMbrave050 study of Tecentriq-Avastin met primary endpoint 01/12/23 Roche announces EC approval of Xofluza in children aged one year and above 01/09/23 Sonnet BioTherapeutics, Roche collaborate for SON-1010 with atezolizumab 01/06/23 Genentech announces FDA acceptance of, grants priority review for glofitamab BLA RHHBY Roche $40.05 / +0.1 (+0.25%) 01/26/23 Citi Novartis downgraded to Neutral from Buy at Citi 01/24/23 Evercore ISI TG Therapeutics price target raised to $25 from $16 at Evercore ISI 01/18/23 Deutsche Bank Deutsche Bank bearish on Roche heading into FY23, cuts to Sell 01/18/23 Deutsche Bank Roche downgraded to Sell from Hold at Deutsche Bank RHHBY Roche $40.05 / +0.1 (+0.25%) 10/18/22 Roche reports nine months group sales CHF 47.04B vs. CHF 46.68B last year RHHBY Roche $40.05 / +0.1 (+0.25%) 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports RHHBY Roche $40.05 / +0.1 (+0.25%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today 01/30/23 Biopharma/Biotechs 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/02/23 Roche - RHHBY
Downgrade	Novartis downgraded to Neutral from Buy at Citi » 04:31 01/26/23 01/26 04:31 01/26/23 04:31 NVS Novartis $92.81 / +0.775 (+0.84%) , NVO Novo Nordisk $138.94 / -1.06 (-0.76%) , AZN AstraZeneca $66.62 / +0.335 (+0.51%) , MRK Merck $108.60 / +0.065 (+0.06%) , RHHBY Roche $40.05 / +0.1 (+0.25%) Citi analyst Andrew Baum… Citi analyst Andrew Baum downgraded Novartis (NVS) to Neutral from Buy with a CHF 86 price target. The shares have outperformed all European pharma majors except Novo Nordisk (NVO) and AstraZeneca (AZN) due to the impact of management action in the last six months, aided by some rotation out of Roche (RHHBY), the analyst tells investors in a research note. Citi reduced Novartis earnings estimates to by up to 8% to reflect a more cautious outlook for Leqvio given competitive pressures from Merck's (MRK) oral PCSK-9 MK-0616 in the U.S. commercial and outside the U.S. market. The firm also highlights material ongoing supply constraints hindering Pluvicto's U.S. launch in prostate cancer. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options RHHBY NVS NVO MRK AZN RHHBY Roche $40.05 / +0.1 (+0.25%) 01/19/23 Roche says Phase 3 IMbrave050 study of Tecentriq-Avastin met primary endpoint 01/12/23 Roche announces EC approval of Xofluza in children aged one year and above 01/09/23 Sonnet BioTherapeutics, Roche collaborate for SON-1010 with atezolizumab 01/06/23 Genentech announces FDA acceptance of, grants priority review for glofitamab BLA NVS Novartis $92.81 / +0.775 (+0.84%) 01/23/23 Novartis unit Sandoz to acquire Mycamine from Astellas 01/09/23 Ionis Pharmaceuticals, Royalty Pharma enter $1.1B royalty agreement 01/06/23 Sandoz Canada launches PrSandoz Sitagliptin, PrSandoz Sitagliptin Metformin 12/22/22 Sandoz Canada supports Ontario policy change on biosimilars NVO Novo Nordisk $138.94 / -1.06 (-0.76%) 01/24/23 Novo Nordisk trading resumes 01/24/23 Novo Nordisk trading halted, volatility trading pause 01/13/23 Novo Nordisk announces FDA approval of label update for Rybelsus 01/12/23 California AG files suit against drugmakers, PBMs over insulin prices MRK Merck $108.60 / +0.065 (+0.06%) 01/25/23 Merck to stop Phase 3 KEYNOTE-991 trial 01/25/23 Merck reports 'positive' results from Phase 3 KEYNOTE-966 trial 01/18/23 Merck picks Perceiv AI for inaugural Digital Sciences Studio cohort 01/11/23 Merck completes tender offer to acquire Imago BioSciences AZN AstraZeneca $66.62 / +0.335 (+0.51%) 01/24/23 Thermo Fisher, AstraZeneca team on CDx test for Tagrisso 01/23/23 AstraZeneca commences tender offer to acquire CinCor Pharma for $26.00 per share 01/18/23 Hutchmed announces inclusion of ORPATHYS in China's NRDL 01/17/23 AIM ImmunoTech in pancreatic cancer research pacts with AstraZeneca NVS NVO AZN MRK RHHBY NVS Novartis $92.81 / +0.775 (+0.84%) 01/24/23 Lake Street Harrow Health price target raised to $24 from $17 at Lake Street 01/06/23 Morgan Stanley Novartis downgraded to Underweight from Equal Weight at Morgan Stanley 01/03/23 JPMorgan Novartis upgraded to Neutral from Underweight at JPMorgan 12/14/22 UBS Novartis price target raised to CHF 84 from CHF 82 at UBS NVO Novo Nordisk $138.94 / -1.06 (-0.76%) 01/18/23 Deutsche Bank Deutsche Bank bearish on Roche heading into FY23, cuts to Sell 01/03/23 JPMorgan Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan 01/03/23 JPMorgan Novo Nordisk added to Analyst Focus List at JPMorgan 12/12/22 Cowen Novo Nordisk price target raised to $145 from $130 at Cowen AZN AstraZeneca $66.62 / +0.335 (+0.51%) 01/18/23 Berenberg AstraZeneca price target raised to 126 GBp from 118 GBp at Berenberg 01/12/23 Guggenheim Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks 01/12/23 Barclays CinCor Pharma downgraded to Equal Weight from Overweight at Barclays 01/05/23 BMO Capital AstraZeneca initiated with an Outperform at BMO Capital MRK Merck $108.60 / +0.065 (+0.06%) 01/04/23 BofA Merck upgraded to Buy at BofA on consistent revenue upside 01/04/23 BofA Merck upgraded to Buy from Neutral at BofA 01/03/23 Wells Fargo Merck price target raised to $125 from $110 at Wells Fargo 01/03/23 Cowen Merck price target raised to $120 from $108 at Cowen RHHBY Roche $40.05 / +0.1 (+0.25%) 01/24/23 Evercore ISI TG Therapeutics price target raised to $25 from $16 at Evercore ISI 01/18/23 Deutsche Bank Roche downgraded to Sell from Hold at Deutsche Bank RHHBY NVS NVO MRK AZN RHHBY Roche $40.05 / +0.1 (+0.25%) 10/18/22 Roche reports nine months group sales CHF 47.04B vs. CHF 46.68B last year NVS Novartis $92.81 / +0.775 (+0.84%) 10/25/22 Novartis confirms mid single digit sales, core operating income guidance 10/25/22 Novartis reports Q3 core EPS $1.58 vs. $1.71 last year 09/22/22 Novartis sees 4% sales CAGR through 2027 NVO Novo Nordisk $138.94 / -1.06 (-0.76%) 11/02/22 Novo Nordisk reports 9-month EPS DKK18.42 vs. DKK15.98 last year 08/03/22 Novo Nordisk raises 2022 sales growth outlook to 12%-16% 08/03/22 Novo Nordisk reports Q2 EBIT DKK 18.39B, consensus DKK 18.13B MRK Merck $108.60 / +0.065 (+0.06%) 10/27/22 Merck raises FY22 adjusted EPS view to $7.32-$7.37 from $7.25-$7.35 10/27/22 Merck reports Q3 adjusted EPS $1.85, consensus $1.71 10/26/22 Notable companies reporting before tomorrow's open AZN AstraZeneca $66.62 / +0.335 (+0.51%) 11/10/22 AstraZeneca raises FY22 core EPS view to high 20s to low 30s percentage 11/10/22 AstraZeneca reports Q3 core EPS $1.67, YTD core EPS $5.28 07/29/22 AstraZeneca backs FY22 core EPS view up by mid to high twenties percentage 07/29/22 AstraZeneca reports Q2 core EPS $1.72, up 89% year-over-year RHHBY NVS NVO MRK AZN RHHBY Roche $40.05 / +0.1 (+0.25%) 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports NVS Novartis $92.81 / +0.775 (+0.84%) 12/29/22 Novartis to pay $245M to settle lawsuit on Exforge medicine, Bloomberg reports 11/16/22 Novartis exploring sale of ophthalmology, respiratory units, Bloomberg says 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 10/13/22 Novartis to cut up to 400 jobs from Dublin operations, RTE reports NVO Novo Nordisk $138.94 / -1.06 (-0.76%) 08/13/22 Eli Lilly, Novo Nordisk weight-loss drugs could be blockbusters, Barron's says MRK Merck $108.60 / +0.065 (+0.06%) 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/11/23 Merck, Pfizer rebuff China's efforts to cut Covid drug prices, Bloomberg says 12/30/22 Merck's Covid treatment gets conditional approval in China, Reuters reports AZN AstraZeneca $66.62 / +0.335 (+0.51%) 12/09/22 AstraZeneca says Dato-DXd 'continued to demonstrate encouraging responses' 11/10/22 AstraZeneca drops plans to submit COVID-19 vaccine to U.S. FDA, WSJ reports 08/23/22 AstraZeneca tells Reuters it may not stay in vaccine business long-term RHHBY NVS NVO MRK AZN RHHBY Roche $40.05 / +0.1 (+0.25%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today NVS Novartis $92.81 / +0.775 (+0.84%) 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 12/12/22 Biotech Alert: Searches spiking for these stocks today 09/15/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations NVO Novo Nordisk $138.94 / -1.06 (-0.76%) 11/04/22 Biotech Alert: Searches spiking for these stocks today 10/03/22 Biotech Alert: Searches spiking for these stocks today 09/01/22 What You Missed On Wall Street On Thursday 09/01/22 What You Missed On Wall Street This Morning MRK Merck $108.60 / +0.065 (+0.06%) 01/04/23 What You Missed On Wall Street This Morning 01/04/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/15/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations AZN AstraZeneca $66.62 / +0.335 (+0.51%) 01/19/23 Biotech Alert: Searches spiking for these stocks today 01/09/23 What You Missed On Wall Street On Monday 01/09/23 What You Missed On Wall Street This Morning 01/05/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/30/23 Biopharma/Biotechs 02/01/23 Emerging Biotechnology 03/09/23 Biopharma/Biotech 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/24/23 Annual Meeting of AAAAI 2023 02/01/23 Novo Nordisk - NVO 02/01/23 Novartis - NVS 02/02/23 Merck - MRK 02/02/23 Roche - RHHBY 00:00 Today PDUFA Date for new sBLA for KEYTRUDA NVS MRK AZN NVS Novartis $92.81 / +0.775 (+0.84%) 01/09/23 Novartis call volume above normal and directionally bullish 12/16/22 Novartis call volume above normal and directionally bullish 10/06/22 Novartis put volume heavy and directionally bearish 08/09/22 Largest borrow rate increases among liquid names MRK Merck $108.60 / +0.065 (+0.06%) 01/10/23 Largest borrow rate increases among liquid names 12/07/22 Largest borrow rate increases among liquid names 11/14/22 Early notable gainers among liquid option names on November 14th 10/10/22 Early notable gainers among liquid option names on October 10th AZN AstraZeneca $66.62 / +0.335 (+0.51%) 11/11/22 AstraZeneca put volume heavy and directionally bearish 11/08/22 AstraZeneca put volume heavy and directionally bearish 10/11/22 AstraZeneca call volume above normal and directionally bullish 09/12/22 AstraZeneca call volume above normal and directionally bullish

Wednesday
Recommendations	J&J conference call comments 'a good sign' for Protagonist, says JMP Securities » 14:31 01/25/23 01/25 14:31 01/25/23 14:31 PTGX Protagonist Therapeutics $12.92 / +0.23 (+1.81%) , JNJ Johnson & Johnson $168.79 / +0.49 (+0.29%) JMP Securities analyst… JMP Securities analyst Jonathan Wolleben reiterated an Outperform rating and $21 price target on Protagonist Therapeutics (PTGX) after Johnson & Johnson (JNJ) highlighted the upcoming data and opportunity for the oral IL-23R antagonist PN-235 on its quarterly call. JMP said that the mention of PN-235 on the call seems like a good sign for the ongoing partnership with Phase 2 data from both the FRONTIER 1 and SUMMIT trials for psoriasis coming this year. The firm views the partnership with Johnson & Johnson and the progress on PN-235 as validation for Protagonist's developmental capabilities and considers downstream payments from the partnership as upside to the firm's valuation. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PTGX JNJ PTGX Protagonist Therapeutics $12.92 / +0.23 (+1.81%) 11/02/22 Protagonist Therapeutics names Arturo Molina as Chief Medical Officer JNJ Johnson & Johnson $168.79 / +0.49 (+0.29%) 01/24/23 Johnson & Johnson says assuming a lot of inflationary carryover in 2023 01/24/23 Johnson & Johnson sees 'above market growth' in Pharmaceutical segment in FY23 01/24/23 Johnson & Johnson expects FY23 OPEX leverage offset by inflationary pressures 01/24/23 Johnson & Johnson says capital allocation strategy 'remains unchanged' PTGX JNJ PTGX Protagonist Therapeutics $12.92 / +0.23 (+1.81%) 01/17/23 Piper Sandler Piper Sandler 'excited' about Protagonist ahead of PN-235 data 11/10/22 H.C. Wainwright Protagonist Therapeutics price target lowered to $33 from $50 at H.C. Wainwright 08/25/22 JMP Securities Protagonist Therapeutics resumed with an Outperform at JMP Securities 05/17/22 Piper Sandler Protagonist Therapeutics price target lowered to $35 from $60 at Piper Sandler JNJ Johnson & Johnson $168.79 / +0.49 (+0.29%) 01/24/23 H.C. Wainwright Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright 01/18/23 SVB Securities Moderna price target raised to $111 from $102 at SVB Securities 01/06/23 BofA Fate Therapeutics double downgraded to Underperform at BofA 01/06/23 Wedbush Fate Therapeutics downgraded to Neutral from Outperform at Wedbush PTGX JNJ PTGX Protagonist Therapeutics $12.92 / +0.23 (+1.81%) 11/08/22 Protagonist Therapeutics reports Q3 EPS (64c), consensus (87c) 08/04/22 Protagonist Therapeutics reports Q2 EPS (84c), consensus (93c) JNJ Johnson & Johnson $168.79 / +0.49 (+0.29%) 01/24/23 Johnson & Johnson sees FY23 adjusted EPS $10.45- $10.65, consensus $10.33 01/24/23 Johnson & Johnson sees FY23 adjusted operational EPS $10.40-$10.60 01/24/23 Johnson & Johnson sees FY23 adjusted operation EPS $10.50, consensus $10.33 01/24/23 Johnson & Johnson reports Q4 adjusted EPS $2.35, consensus $2.23 JNJ JNJ Johnson & Johnson $168.79 / +0.49 (+0.29%) 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/09/23 J&J may look for deals that boost eye care, surgical robots units, Reuters says 12/04/22 J&J says won't make offer for Horizon Therapeutics, Bloomberg reports 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says JNJ JNJ Johnson & Johnson $168.79 / +0.49 (+0.29%) 01/24/23 What You Missed On Wall Street On Tuesday 01/24/23 What You Missed On Wall Street This Morning 01/24/23 Fly Intel: Pre-market Movers 01/07/23 Short Report: Bad News Bears continue to claw Silvergate, Futu Holdings 03/09/23 Biopharma/Biotech 01/27/23 Protagonist Therapeutics - PTGX JNJ JNJ Johnson & Johnson $168.79 / +0.49 (+0.29%) 01/24/23 Unusually active option classes on open January 24th 01/20/23 Johnson & Johnson put buyer realizes 33% same-day gains 01/11/23 Unusually active option classes on open January 11th 12/22/22 Johnson & Johnson put volume heavy and directionally bearish

Tuesday
On The Fly	What You Missed On Wall Street On Tuesday » 16:32 01/24/23 01/24 16:32 01/24/23 16:32 XMTR Xometry $31.16 / +1.94 (+6.64%) , LYV Live Nation $77.00 / +1.045 (+1.38%) , RIVN Rivian Automotive $18.05 / -0.03 (-0.17%) , F Ford $12.74 / -0.065 (-0.51%) , PARA Paramount $20.83 / -0.33 (-1.56%) , PARAA Paramount $24.36 / -0.21 (-0.85%) , GE General Electric $80.72 / +0.925 (+1.16%) , JNJ Johnson & Johnson $168.30 / -0.065 (-0.04%) , AMZN Amazon.com $96.35 / -1.16 (-1.19%) , GOOGL Alphabet $97.68 / -2.095 (-2.10%) , GOOG Alphabet $99.20 / -1.99 (-1.97%) , $ECON Economic Data / + , SPX S&P 500 / + , SPY SPDR S&P 500 ETF Trust $400.15 / -0.44 (-0.11%) , PTON Peloton $11.06 / -0.585 (-5.02%) , LULU Lululemon $311.35 / -4.73 (-1.50%) , LYFT Lyft $15.29 / -0.13 (-0.84%) , AMD AMD $74.72 / -1.82 (-2.38%) , TGT Target $163.54 / -1.1 (-0.67%) , CBAY CymaBay $7.63 / +1.025 (+15.52%) , TGTX TG Therapeutics $14.46 / +1.775 (+13.99%) , SAVA Cassava Sciences $29.44 / -7.01 (-19.23%) , MMM 3M $115.00 / -7.67 (-6.25%) , MGA Magna $60.75 / -4.71 (-7.20%) , VZ Verizon $40.42 / +0.795 (+2.01%) , TRV Travelers $193.23 / +6.57 (+3.52%) , LMT Lockheed Martin $449.14 / +7.5 (+1.70%) , DHI D.R. Horton $97.04 / +1.365 (+1.43%) , PD PagerDuty $26.52 / -2.33 (-8.08%) Get caught up quickly on… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options Technical Analysis XMTR VZ TRV TGTX TGT SPY SPX SAVA RIVN PTON PD PARAA PARA MMM MGA LYV LYFT LULU LMT JNJ GOOGL GE F DHI CBAY AMZN AMD XMTR Xometry $31.16 / +1.94 (+6.64%) 11/02/22 Xometry CEO sells $1.2M in common stock 10/05/22 Xometry CEO sells $1.17M in common stock 10/03/22 Xometry appoints Matt Leibel as CTO, Brendan Sterne as CPO 08/25/22 Xometry, CCBC announce public-private partnership for two-year scholarships VZ Verizon $40.42 / +0.795 (+2.01%) 01/24/23 Verizon trading resumes 01/24/23 Verizon trading halted, volatility trading pause 01/24/23 Verizon expects capital spending of $17B in 2024 TRV Travelers $193.23 / +6.57 (+3.52%) 01/24/23 Travelers reports book value per share 92.90, down 22% from year-end 2021 10/19/22 Travelers reports book value per share of $84.94, down 27% from September 30 09/22/22 Google Cloud and Travelers to create data ecosystem for insurance underwriting TGTX TG Therapeutics $14.46 / +1.775 (+13.99%) 12/29/22 TG Therapeutics says about 6-9 months behind U.S. on potential EU approval 12/29/22 TG Therapeutics says Briumvi annual maintenance WAC price $59,000 12/29/22 TG says 'ideally' Briumvi to be in centers within 30-45 days of new year 12/29/22 TG Therapeutics doesn't see need to raise additional capital at this time TGT Target $163.54 / -1.1 (-0.67%) 01/09/23 Mattel's Fisher-Price re-announces recall of 4.7M Rock 'n Play Sleepers 12/22/22 Target recalls roughly 204,000 children's weighted blankets after two deaths 11/25/22 Target announces Cyber Monday sales event from Nov. 27-28 11/17/22 Target announces largest Black Friday week sale ever from Nov. 20-26 SPY SPDR S&P 500 ETF Trust $400.15 / -0.44 (-0.11%) 11/14/22 Jana made new buy Freshpet top holding in Q3, also bought Momentive SPX S&P 500 / + 12/14/22 SEC proposes rules to enhance competition for retail order flow execution 11/07/22 SEC Chief Prashant Yerramalli departing Dec. 31, Amanda Fischer to replace SAVA Cassava Sciences $29.44 / -7.01 (-19.23%) 01/24/23 Cassava Sciences falls after simufilam data for Alzheimer's disease treatment 01/24/23 Cassava Sciences announces clinical results in Phase 2 study of simufilam 12/20/22 Cassava Sciences announces passing of CMO Nadav Friedmann 12/06/22 Cassava Sciences completes dosing in open-label study of simufilam RIVN Rivian Automotive $18.05 / -0.03 (-0.17%) 01/03/23 Rivian Automotive produced 10,020 vehicles in Q4 12/12/22 Rivian Automotive pauses plans to produce electric commercial vans in Europe 12/06/22 Vietnam-based EV maker VinFast plans for U.S. IPO 12/05/22 Rivian Automotive enters wind energy deal with Apex Clean Energy PTON Peloton $11.06 / -0.585 (-5.02%) 01/17/23 Peloton appoints Leslie Berland as CMO 01/09/23 Verizon offers four months of Peloton app free through +play beta 01/05/23 Peloton to pay $19M civil penalty for failure to immediately report hazards 12/26/22 Peloton to offer refurbished bikes with Peloton Certified Refurbished PD PagerDuty $26.52 / -2.33 (-8.08%) 01/24/23 PagerDuty announces 7% reduction in headcount 01/24/23 PagerDuty Chief Revenue Officer leaving, Kmet appointed SVP of Global Field Ops 01/20/23 PagerDuty rises 6.1% 09/08/22 PagerDuty names Sesh Tirumala as CIO, Heather Hinton CISO PARAA Paramount $24.36 / -0.21 (-0.85%) 10/12/22 CJ 4DPlex says 'Top Gun: Maverick' grossed $60M in its premier formats 08/03/22 Paramount+ to launch as a Premium Subscription within Roku Channel 07/25/22 NFL launches exclusive streaming subscription service NFL+ PARA Paramount $20.83 / -0.33 (-1.56%) 01/23/23 Association of Pickleball Professionals announces broadcast deals with CBS, ESPN 12/08/22 Paramount+ launches in Germany, Switzerland and Austria 12/07/22 Paramount CEO says view of 2023 as peak streaming investment year hasn't changed 12/06/22 Paramount CEO sees Q4 ad business 'a bit below' Q3 MMM 3M $115.00 / -7.67 (-6.25%) 01/24/23 NYSE sees unusual number of halted stocks at open due to exchange issues 01/24/23 3M trading resumes 01/24/23 3M trading halted, volatility trading pause 12/20/22 3M to exit PMAS manufacturing by 2025 MGA Magna $60.75 / -4.71 (-7.20%) 01/24/23 Magna falls -8.9% 01/18/23 Magna ClearView vision system debuts in Ram trucks 12/21/22 Magna introduces Morphing Surfaces technology 12/20/22 Magna to acquire Veoneer Active Safety business from SSW for $1.53B in cash LYV Live Nation $77.00 / +1.045 (+1.38%) 01/20/23 Live Nation, KIDZ BOP announce 2023 KIDZ BOP Never Stop Tour 01/09/23 Live Nation down 1% after launching $850M convertible senior notes offering 12/01/22 Live Nation director Iovine acquires 13,740 common shares 11/23/22 Congress to hold hearing on Ticketmaster issue after Taylor Swift mess LYFT Lyft $15.29 / -0.13 (-0.84%) 12/13/22 Wallbox and Lyft team to boost home EV charging access in North America 12/13/22 EVgo, Lyft launch new partnership to accelerate rideshare electrification 11/03/22 Lyft: No change to Q3 revenue, margin, adjusted EBITDA guidance 11/03/22 Lyft confirms plans to terminate 13% of employees, or about 683 workers LULU Lululemon $311.35 / -4.73 (-1.50%) 01/12/23 lululemon teams with Nedap to advance RFID technology across stores 01/09/23 Lululemon falls 14% to $282.02 after revising Q4 guidance 12/08/22 Lululemon falls 9% to $340.75 after Q3 results and guidance 12/08/22 Lululemon reports Q3 SSS up 22% or 25% on constant FX basis LMT Lockheed Martin $449.14 / +7.5 (+1.70%) 01/24/23 Lockheed Martin announces successful first flight of F-16 Block 70 aircraft 01/24/23 Lockheed Martin says business is 'well-positioned' for long-term growth 01/24/23 Lockheed Martin on pace to build 156 F-35 fight jets by 2025 01/24/23 Lockheed Martin says returned 178% of FCF in 2022 JNJ Johnson & Johnson $168.30 / -0.065 (-0.04%) 01/24/23 Johnson & Johnson says assuming a lot of inflationary carryover in 2023 01/24/23 Johnson & Johnson sees 'above market growth' in Pharmaceutical segment in FY23 01/24/23 Johnson & Johnson expects FY23 OPEX leverage offset by inflationary pressures 01/24/23 Johnson & Johnson says capital allocation strategy 'remains unchanged' GOOGL Alphabet $97.68 / -2.095 (-2.10%) 01/24/23 Google's Dan Taylor says DOJ lawsuit 'tries to rewrite history' 01/24/23 States, Department of Justice sue Google alleging advertising 'monopoly' 01/24/23 Justice Department, eight states file antitrust suit against Google 01/20/23 Alphabet to reduce workforce by approximately 12,000 roles GE General Electric $80.72 / +0.925 (+1.16%) 01/24/23 GE: Board conversations on capital allocation 'fundamentally different' 01/24/23 General Electric 'acting with urgency' in Power business 01/24/23 General Electric CEO: GE, CFM departures close to 90% of 2019 levels 01/24/23 General Electric: Inflation Reduction Act a 'game changer' F Ford $12.74 / -0.065 (-0.51%) 01/23/23 Ford sees Q4 pre-tax remeasurement gain of roughly $50M from pension, OPEB plans 01/18/23 EU passenger car registrations up 12.8% in December 01/10/23 RMI launches virtual power plant partnership with GM, Google, Ford 01/05/23 Ford reports December U.S. sales 179,279, up 3.2% DHI D.R. Horton $97.04 / +1.365 (+1.43%) 01/24/23 D.R. Horton saw 'slight' improvement in cancellation rate in January 01/24/23 D.R. Horton: Goal is to generate FY23 revenue slightly higher than FY22 12/15/22 D.R. Horton acquires homebuilding operations of Riggins Custom Homes 11/14/22 Soros Fund Management buys Sierra Wireless, exits Kinder Morgan in Q3 CBAY CymaBay $7.63 / +1.025 (+15.52%) 01/24/23 CymaBay up 11% at $7.32 after pricing stock offering above prior close 01/08/23 CymaBay announces collaboration with Kaken to develop, commercialize Seladelpar 11/04/22 CymaBay presents additional analyses from studies of seladelpar 11/01/22 CymaBay appoints McWherter as President of Research, Development AMZN Amazon.com $96.35 / -1.16 (-1.19%) 01/24/23 Amazon launches RxPass benefit to Prime members for $5 per month subscription 01/23/23 Amazon Web Services launches second infrastructure region in Australia 01/23/23 Amazon and payment platform Stripe in expanded global pact 01/22/23 Amazon Web Services plans to invest $35B in Virginia by 2040 AMD AMD $74.72 / -1.82 (-2.38%) 01/20/23 AMD identified as respondent in ITC investigation of certain integrated circuits 01/19/23 AMD adaptive computing tech enables DENSO LiDAR system 01/11/23 AMD CFO Devinder Kumar to retire, Jean Hu appointed new CFO 12/20/22 EU opens antitrust probe into Broadcom's proposed $61B VMware bid XMTR LYV RIVN F PARA PARAA GE JNJ AMZN GOOGL GOOG $ECON SPX SPY PTON LULU LYFT AMD TGT CBAY TGTX SAVA MMM MGA VZ TRV LMT DHI PD XMTR Xometry $31.16 / +1.94 (+6.64%) 12/14/22 Lake Street Xometry initiated with a Sell at Lake Street 12/13/22 Citi Xometry initiated with a Buy at Citi 11/11/22 UBS Xometry price target lowered to $45 from $55 at UBS 08/24/22 JPMorgan JPMorgan cuts Xometry target but still sees 46% upside potential LYV Live Nation $77.00 / +1.045 (+1.38%) 12/08/22 Jefferies Live Nation price target lowered to $92 from $120 at Jefferies 11/30/22 Morgan Stanley Live Nation price target lowered to $80 from $95 at Morgan Stanley 11/28/22 Citi Live Nation upgraded to Buy from Neutral at Citi 11/22/22 Redburn Redburn starts Live Nation with a Neutral RIVN Rivian Automotive $18.05 / -0.03 (-0.17%) 01/25/23 Morgan Stanley Rivian Automotive price target lowered to $28 from $55 at Morgan Stanley 01/19/23 Deutsche Bank Rivian Automotive price target lowered to $28 from $43 at Deutsche Bank 01/11/23 Goldman Sachs Goldman continues to prefer Tesla and GM among automakers 01/10/23 Goldman Sachs Rivian Automotive price target lowered to $19 from $41 at Goldman Sachs F Ford $12.74 / -0.065 (-0.51%) 01/25/23 JPMorgan Ford price target lowered to $15 from $16 at JPMorgan 12/21/22 Morgan Stanley Tesla shedding $600B of value presents buying opportunity, says Morgan Stanley 12/05/22 Jefferies Fox Factory price target raised to $135 from $120 at Jefferies PARA Paramount $20.83 / -0.33 (-1.56%) 01/12/23 Guggenheim Paramount price target raised to $22 from $20 at Guggenheim 01/04/23 Macquarie Paramount price target lowered to $15 from $16 at Macquarie 12/23/22 Loop Capital Paramount cut to Sell at Loop Capital amid declining earnings and cash flow 12/23/22 Loop Capital Paramount downgraded to Sell from Hold at Loop Capital PARAA Paramount $24.36 / -0.21 (-0.85%) GE General Electric $80.72 / +0.925 (+1.16%) 01/25/23 BofA General Electric price target raised to $92 from $85 at BofA 01/12/23 UBS General Electric price target lowered to $87 from $98 at UBS 01/09/23 BofA General Electric price target lowered to $85 from $105 at BofA 12/16/22 Barclays General Electric price target raised to $96 from $92 at Barclays JNJ Johnson & Johnson $168.30 / -0.065 (-0.04%) 01/24/23 H.C. Wainwright Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright 01/18/23 SVB Securities Moderna price target raised to $111 from $102 at SVB Securities 01/06/23 BofA Fate Therapeutics double downgraded to Underperform at BofA 01/06/23 Wedbush Fate Therapeutics downgraded to Neutral from Outperform at Wedbush AMZN Amazon.com $96.35 / -1.16 (-1.19%) 01/25/23 BofA Azure guidance indicates AWS will remain concern into earnings, says BofA 01/25/23 UBS Amazon.com price target lowered to $118 from $121 at UBS 01/24/23 Citi Amazon RxPass a 'credible threat' to GoodRx, says Citi 01/18/23 MKM Partners Amazon.com price target lowered to $125 from $145 at MKM Partners GOOGL Alphabet $97.68 / -2.095 (-2.10%) 01/25/23 MKM Partners Alphabet price target lowered to $120 from $130 at MKM Partners 01/25/23 Credit Suisse Alphabet price target raised to $145 from $128 at Credit Suisse 01/22/23 Citi Alphabet workforce reduction a positive catalyst, says Citi 01/20/23 MKM Partners Meta Platforms price target raised to $155 from $140 at MKM Partners GOOG Alphabet $99.20 / -1.99 (-1.97%) 01/24/23 Credit Suisse Credit Suisse sees 8% Alphabet target cut in 'maximum value destruction' 01/24/23 Raymond James Alphabet price target lowered to $116 from $120 at Raymond James 01/24/23 Raymond James Alphabet price target lowered to $116 from $120 at Raymond James $ECON Economic Data / + 10/31/22 JPMorgan Central bank tightening has likely peaked, says JPMorgan 10/07/22 JPMorgan JPMorgan changes November rate hike assumption after jobs data 09/26/22 JPMorgan JPMorgan says stocks oversold amid 'encouraging' inflation signs 09/23/22 Goldman Sachs Goldman Sachs lowers S&P 500 year-end target to 3,600 SPX S&P 500 / + SPY SPDR S&P 500 ETF Trust $400.15 / -0.44 (-0.11%) PTON Peloton $11.06 / -0.585 (-5.02%) 01/24/23 MKM Partners MKM Partners positive on Peloton heading into earnings 01/24/23 Baird Peloton downgraded to Neutral from Outperform at Baird 11/21/22 Cowen Peloton downgraded to Market Perform from Outperform at Cowen 11/07/22 Citi Peloton price target lowered to $18 from $23 at Citi LULU Lululemon $311.35 / -4.73 (-1.50%) 01/24/23 Bernstein Lululemon downgraded to Underperform from Market Perform at Bernstein 01/23/23 Jefferies Jefferies store checks find 'flaws' in Lululemon merchandising 01/13/23 Citi Lululemon price target lowered to $350 from $400 at Citi 01/13/23 Barclays Lululemon price target lowered to $394 from $445 at Barclays LYFT Lyft $15.29 / -0.13 (-0.84%) 01/24/23 KeyBanc KeyBanc upgrades Lyft on 'meaningful opportunity' for EBITDA lift 01/23/23 KeyBanc Lyft upgraded to Overweight from Sector Weight at KeyBanc 01/09/23 Jefferies Lyft assumed with a Hold at Jefferies 01/09/23 Piper Sandler Lyft price target lowered to $16 from $37 at Piper Sandler AMD AMD $74.72 / -1.82 (-2.38%) 01/24/23 Cowen AMD remains in a very strong competitive position, says Cowen 01/24/23 Bernstein AMD downgraded to Market Perform from Outperform at Bernstein 01/23/23 Truist AMD price target raised to $79 from $70 at Truist 01/23/23 Barclays AMD upgraded to Overweight from Equal Weight at Barclays TGT Target $163.54 / -1.1 (-0.67%) 01/23/23 Oppenheimer Target initiated with an Outperform at Oppenheimer 01/04/23 Wells Fargo Wells Fargo downgrades Target to Equal Weight, lowers price target to $142 01/04/23 Wells Fargo Target downgraded to Equal Weight from Overweight at Wells Fargo 12/21/22 Gordon Haskett Gordon Haskett downgrades Target on 'meaningfully eroded' traffic CBAY CymaBay $7.63 / +1.025 (+15.52%) 01/09/23 Piper Sandler CymaBay collaboration in Japan further de-risks PBC data, says Piper Sandler 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 05/18/22 B. Riley CymaBay price target lowered to $8 from $10 at B. Riley 05/16/22 H.C. Wainwright CymaBay price target lowered to $10 from $12 at H.C. Wainwright TGTX TG Therapeutics $14.46 / +1.775 (+13.99%) 01/24/23 Evercore ISI TG Therapeutics price target raised to $25 from $16 at Evercore ISI 12/30/22 Jefferies TG Therapeutics price target raised to $23 from $19 at Jefferies 12/30/22 Evercore ISI TG Therapeutics price target raised to $16 from $11 at Evercore ISI 12/29/22 B. Riley TG Therapeutics price target raised to $23 from $17 at B. Riley SAVA Cassava Sciences $29.44 / -7.01 (-19.23%) 01/25/23 B. Riley Cassava Sciences price target lowered to $28 from $44 at B. Riley 01/24/23 H.C. Wainwright H.C. Wainwright positive on Cassava data, says buy the selloff 11/29/22 Univest Securities Cassava Sciences price target lowered to $11 from $12 at Univest Securities 11/16/22 B. Riley Cassava Sciences downgraded to Neutral at B. Riley amid limited disclosures MMM 3M $115.00 / -7.67 (-6.25%) 01/25/23 Wells Fargo 3M price target lowered to $115 from $125 at Wells Fargo 01/25/23 UBS 3M price target lowered to $115 from $124 at UBS 01/25/23 Barclays 3M price target lowered to $122 from $130 at Barclays 12/09/22 Citi 3M price target raised to $126 from $117 at Citi MGA Magna $60.75 / -4.71 (-7.20%) 01/25/23 TD Securities Magna downgraded to Hold from Buy at TD Securities 01/13/23 Citi Magna price target raised to $66 from $62 at Citi 01/09/23 BofA Magna downgraded to Neutral from Buy at BofA 12/14/22 Wells Fargo Magna downgraded on likely sector correction at Wells Fargo VZ Verizon $40.42 / +0.795 (+2.01%) 01/25/23 Cowen Verizon price target lowered to $49 from $55 at Cowen 01/25/23 RBC Capital Verizon price target lowered to $40 from $42 at RBC Capital 01/13/23 Truist American Tower price target lowered to $275 from $325 at Truist 12/19/22 MoffettNathanson AT&T downgraded to Underperform at MoffettNathanson after 'dramatic bounce' TRV Travelers $193.23 / +6.57 (+3.52%) 01/25/23 MKM Partners Travelers price target raised to $230 from $220 at MKM Partners 01/25/23 Raymond James Travelers price target raised to $220 from $200 at Raymond James 01/19/23 BMO Capital Travelers initiated with an Outperform at BMO Capital 01/10/23 Evercore ISI Hartford downgraded at Evercore ISI, more relative upside seen elsewhere LMT Lockheed Martin $449.14 / +7.5 (+1.70%) 01/25/23 Credit Suisse Lockheed Martin price target raised to $408 from $384 at Credit Suisse 01/25/23 Argus Lockheed Martin a 'value opportunity', says Argus 01/25/23 Wells Fargo Lockheed Martin price target raised to $422 from $417 at Wells Fargo 01/25/23 Susquehanna Lockheed Martin price target raised to $512 from $510 at Susquehanna DHI D.R. Horton $97.04 / +1.365 (+1.43%) 01/25/23 BTIG D.R. Horton price target raised to $108 from $101 at BTIG 01/25/23 JMP Securities D.R. Horton price target raised to $115 from $95 at JMP Securities 01/25/23 Wedbush Wedbush downgrades D.R. Horton to Neutral, lowers price target to $96 01/25/23 Wedbush D.R. Horton downgraded to Neutral from Outperform at Wedbush PD PagerDuty $26.52 / -2.33 (-8.08%) 01/20/23 Morgan Stanley PagerDuty upgraded to Overweight from Equal Weight at Morgan Stanley 12/02/22 Canaccord PagerDuty price target lowered to $31 from $32 at Canaccord 12/02/22 Baird PagerDuty price target lowered to $32 from $35 at Baird 10/26/22 Truist PagerDuty price target lowered to $30 from $35 at Truist XMTR VZ TRV TGTX TGT SAVA RIVN PTON PD PARA MMM MGA LYV LYFT LULU LMT JNJ GOOGL GE F DHI CBAY AMZN AMD XMTR Xometry $31.16 / +1.94 (+6.64%) 11/10/22 Xometry sees Q4 revenue $104M-$106M, consensus $116.11M 11/10/22 Xometry reports Q3 adjusted EPS (11c), consensus (22c) 08/10/22 Xometry sees 2022 revenue $395M-$400M, consensus $397.09M 08/10/22 Xometry sees Q3 revenue $102M-$104M, consensus $103.9M VZ Verizon $40.42 / +0.795 (+2.01%) 01/24/23 Verizon sees 2023 adjusted EPS $4.55-$4.85, consensus $4.99 01/24/23 Verizon reports Q4 adjusted EPS $1.19, consensus $1.19 TRV Travelers $193.23 / +6.57 (+3.52%) 01/24/23 Travelers reports Q4 core EPS $3.40, consensus $3.40 01/17/23 Travelers sees Q4 core EPS $3.40, consensus $4.04 TGTX TG Therapeutics $14.46 / +1.775 (+13.99%) 11/10/22 TG Therapeutics reports Q3 EPS (26c), consensus (39c) 08/08/22 TG Therapeutics reports Q2 EPS (30c), consensus (51c) TGT Target $163.54 / -1.1 (-0.67%) 11/16/22 Target on track to deliver total sales of well over $100B this year, says COO 11/16/22 Target reports Q3 adjusted EPS $1.54, consensus $2.13 11/15/22 Notable companies reporting before tomorrow's open SAVA Cassava Sciences $29.44 / -7.01 (-19.23%) 11/07/22 Cassava Sciences reports Q3 EPS (51c), consensus (48c) 08/03/22 Cassava Sciences reports Q2 EPS (48c), consensus (43c) RIVN Rivian Automotive $18.05 / -0.03 (-0.17%) 11/09/22 Rivian Automotive reports Q3 adjusted EPS ($1.57), consensus ($1.82) 11/09/22 Notable companies reporting after market close 10/27/22 Amazon reports Q3 EPS 28c with Rivian gain, consensus 21c 08/11/22 Rivian Automotive reports Q2 EPS ($1.89), consensus ($1.67) PTON Peloton $11.06 / -0.585 (-5.02%) 11/03/22 Peloton sees Q2 revenue $700M-$725M, consensus $874M 11/03/22 Peloton reports Q1 EPS ($1.20), consensus (64c) 11/02/22 Notable companies reporting before tomorrow's open PD PagerDuty $26.52 / -2.33 (-8.08%) 01/24/23 PagerDuty backs FY23 EPS view (1c)-0c, consensus (1c) 01/24/23 PagerDuty backs Q4 EPS view 2c-3c, consensus 2c 12/01/22 PagerDuty raises FY23 EPS view to (1c)-0c from (12c)-(10c), consensus (11c) 12/01/22 PagerDuty sees Q4 adjusted EPS 2c-3c, consensus 0c PARA Paramount $20.83 / -0.33 (-1.56%) 11/02/22 Paramount reports Q3 adjusted EPS 39c, consensus 43c 11/01/22 Notable companies reporting before tomorrow's open 08/04/22 Paramount reports Q2 EPS 53c, consensus 62c MMM 3M $115.00 / -7.67 (-6.25%) 01/24/23 3M sees FY23 adjusted EPS $8.50-$9.00, consensus $10.22 01/24/23 3M reports Q4 adjusted EPS $2.28, consensus $2.36 01/23/23 Notable companies reporting before tomorrow's open MGA Magna $60.75 / -4.71 (-7.20%) 01/24/23 Magna narrows 2022 revenue view to $37.8B from $37.4B-$38.4B, consensus $37.79B 11/04/22 Magna lowers FY22 revenue view to $37.4B-$38.4B from $37.6B-$39.2B 11/04/22 Magna reports Q3 adjusted EPS $1.07, consensus $1.59 07/29/22 Magna raises FY22 revenue view to $37.6B-$39.2B from $37.3B-$38.9B LYV Live Nation $77.00 / +1.045 (+1.38%) 11/03/22 Live Nation reports Q3 EPS $1.39, consensus $1.03 11/03/22 Notable companies reporting after market close 08/04/22 Live Nation reports Q2 EPS 66c, consensus 51c 08/04/22 Notable companies reporting after market close LYFT Lyft $15.29 / -0.13 (-0.84%) 11/07/22 Lyft sees FY22 revenue $4.65B-$4.85B, consensus $4.08B 11/07/22 Lyft sees Q4 revenue $1.145B-$1.165B, consensus $1.17B 11/07/22 Lyft reports Q3 EPS ($1.18), consensus 7c 11/07/22 Notable companies reporting after market close LULU Lululemon $311.35 / -4.73 (-1.50%) 01/09/23 Lululemon narrows Q4 adjusted EPS view to $4.22-$4.27 from $4.20-$4.30 12/08/22 Lululemon sees FY22 EPS $9.87-$9.97, consensus $9.92 12/08/22 Lululemon sees Q4 EPS $4.20-$4.30, consensus $4.30 12/08/22 Lululemon reports Q3 EPS $2.00, consensus $1.97 LMT Lockheed Martin $449.14 / +7.5 (+1.70%) 01/24/23 Lockheed Martin reports Q4 adjusted EPS $7.79, consensus $7.39 01/24/23 Lockheed Martin sees FY23 EPS about $26.60-$26.90, consensus $26.93 01/24/23 Lockheed Martin reports Q4 EPS $7.40, consensus $7.39 JNJ Johnson & Johnson $168.30 / -0.065 (-0.04%) 01/24/23 Johnson & Johnson sees FY23 adjusted EPS $10.45- $10.65, consensus $10.33 01/24/23 Johnson & Johnson sees FY23 adjusted operational EPS $10.40-$10.60 01/24/23 Johnson & Johnson sees FY23 adjusted operation EPS $10.50, consensus $10.33 01/24/23 Johnson & Johnson reports Q4 adjusted EPS $2.35, consensus $2.23 GOOGL Alphabet $97.68 / -2.095 (-2.10%) 10/25/22 Alphabet reports Q3 EPS $1.06, consensus $1.25 10/25/22 Notable companies reporting after market close 07/26/22 Alphabet reports Q2 EPS $1.21, consensus $1.30 07/26/22 Notable companies reporting after market close GE General Electric $80.72 / +0.925 (+1.16%) 01/24/23 General Electric sees Q1 EPS 10c-15c, consensus 19c 01/24/23 GE sees FY23 organic revenue growth in high single digits ex-HealthCare 01/24/23 General Electric sees FY23 adjusted EPS $1.60-$2.00, consensus $2.37 01/24/23 General Electric reports Q4 adjusted EPS $1.24, consensus $1.13 F Ford $12.74 / -0.065 (-0.51%) 10/26/22 Ford reports Q3 adjusted EPS 39c, consensus 27c 10/26/22 Notable companies reporting after market close 07/27/22 Ford reports Q2 adjusted EPS 68c, consensus 45c 07/27/22 Notable companies reporting after market close DHI D.R. Horton $97.04 / +1.365 (+1.43%) 01/24/23 D.R. Horton sees Q2 revenue $6.3B-$6.7B, consensus $6.53B 01/24/23 D.R. Horton reports Q1 EPS $2.76, consensus $2.26 CBAY CymaBay $7.63 / +1.025 (+15.52%) 11/14/22 CymaBay reports Q3 EPS (28c), consensus (30c) 08/11/22 CymaBay reports Q2 EPS (31c), consensus (30c) AMZN Amazon.com $96.35 / -1.16 (-1.19%) 10/27/22 Amazon sees Q4 revenue $140B-$148B, consensus $155.15B 10/27/22 Notable companies reporting after market close 07/28/22 Amazon reports Q2 AWS net sales $19.73B vs. $14.81B a year ago AMD AMD $74.72 / -1.82 (-2.38%) 11/01/22 AMD cuts FY22 revenue view to $23.5B +/- $300M from $26.3B +/- $300M 11/01/22 AMD sees Q4 revenue $5.5B +/- $300M, consensus $5.85B 11/01/22 AMD reports Q3 EPS 67c, consensus 68c 11/01/22 Notable companies reporting after market close 24 Jan XMTR VZ TGT SPX SAVA RIVN PTON PARAA PARA MMM LYV LYFT LULU LMT JNJ GOOGL GE F DHI AMZN AMD $ECON XMTR Xometry $31.16 / +1.94 (+6.64%) 01/24/23 Culper goes short Xometry, says 'misleads investors' about business 01/24/23 Culper says short Xometry, says recurring revenue narrative 'bogus' VZ Verizon $40.42 / +0.795 (+2.01%) 01/10/23 Best Buy-owned Lively faces complaints after 3G shutdown, WSJ reports 12/20/22 FCC partisan deadlock shields wireless companies from $200M fine, WSJ reports 08/27/22 T-Mobile replaced Verizon atop wireless world, time to buy stock, Barron's says TGT Target $163.54 / -1.1 (-0.67%) 11/14/22 Walmart taking 'aggressive' stance with suppliers, WSJ reports 10/15/22 Shortages have turned to gluts, off-price retailers could benefit, Barron's says 09/03/22 Target's problems won't last forever, time to buy stock, Barron's says SPX S&P 500 / + 10/18/22 Iran shows alliance with Russia's war on Ukraine with weaponry, Guardian says SAVA Cassava Sciences $29.44 / -7.01 (-19.23%) 01/24/23 Cassava's simulfilam no better than placebo, STAT's Feuerstein says 07/27/22 Justice Department opened criminal investigation into Cassava, Reuters says RIVN Rivian Automotive $18.05 / -0.03 (-0.17%) 01/24/23 Rivian's chief lobbyist Chen is set to depart the company, WSJ reports 01/10/23 Top Rivian executives left company in recent months, WSJ says 12/13/22 Geely's premium brand Zeekr confidentially files for U.S. IPO, Reuters says 11/12/22 EV stocks face a reckoning, not all will survive, Barron's says PTON Peloton $11.06 / -0.585 (-5.02%) 10/28/22 Peloton co-founder doubled his pledge shares to cover margin calls, WSJ reports 10/27/22 Peloton drops Kanye West music from platform, NY Post reports 10/11/22 Peloton's Foley faced 'repeated' margin calls on money he borrowed, WSJ reports 10/06/22 Peloton to cut 500 more jobs in turnaround effort, WSJ reports PARAA Paramount $24.36 / -0.21 (-0.85%) 09/13/22 Paramount weighs merging Showtime streaming service into Paramount+, WSJ says 08/08/22 'Top Gun: Maverick' achieves seventh-highest domestic gross ever, CNBC says PARA Paramount $20.83 / -0.33 (-1.56%) 01/24/23 Paramount may add Paramount+ content to Showtime TV channel, WSJ says 01/13/23 YouTube testing new hub of free, ad-supported streaming channels, WSJ reports 01/10/23 Paramount+ orders live-action show based on 'Dungeons & Dragons,' TC says 01/05/23 Paramount sued by 'Romeo and Juliet' stars, WSJ reports MMM 3M $115.00 / -7.67 (-6.25%) 01/04/23 3M attempts to contain liability over 'forever chemicals,' earplugs, WSJ report 12/23/22 Military earplugs cases judge says 3M acted in 'bad faith,' Tribune reports 08/31/22 3M to cut staff as part of cost reduction efforts, Bloomberg reports 08/29/22 3M appeals court ruling over earplug lawsuits, Bloomberg reports LYV Live Nation $77.00 / +1.045 (+1.38%) 01/24/23 Live Nation to face senate at an antitrust-focused hearing, NY Times reports 12/05/22 Taylor Swift fans sue Ticketmaster over ticketing disaster, Deadline reports 11/18/22 Live Nation falls after NY Times report of DOJ Ticketmaster investigation 11/18/22 DOJ opens antirust probe into Live Nation's Ticketmaster, NY Times says LYFT Lyft $15.29 / -0.13 (-0.84%) 01/12/23 Uber drivers struggle to live off their earnings, NY Times reports 12/23/22 IRS postpones gig-tax filing requirement for more than $600 in revenue, WSJ says 12/09/22 Uber sues NYC Taxi comission over driver rate increases, Bloomberg reports 11/03/22 Lyft plans to cut 13% of staff in second round of job cuts, WSJ reports LULU Lululemon $311.35 / -4.73 (-1.50%) 09/30/22 Peloton tells Bloomberg resolved dispute with Lululemon over athletic wear 09/29/22 Peloton suit against Lululemon thrown out by court, Bloomberg reports 09/29/22 Lululemon wins dismissal of patent suit by Peloton, Bloomberg reports 08/17/22 Lululemon D.C. workers withdraw bid for union vote, Bloomberg reports LMT Lockheed Martin $449.14 / +7.5 (+1.70%) 01/13/23 Biden administration seeks congressional OK for F-16 sale to Turkey, WSJ says 01/09/23 Canada finalizes deal to buy 88 of Lockheed's F-35 fighter, Reuters reports 01/06/23 McCarthy's speaker deal includes $75B defense cut, Bloomberg reports 01/04/23 Lagging arms production raises concerns over industry consolidation, WSJ report JNJ Johnson & Johnson $168.30 / -0.065 (-0.04%) 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/09/23 J&J may look for deals that boost eye care, surgical robots units, Reuters says 12/04/22 J&J says won't make offer for Horizon Therapeutics, Bloomberg reports 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says GOOGL Alphabet $97.68 / -2.095 (-2.10%) 01/24/23 Google tells Bloomberg DOJ suit 'doubling down on flawed argument' 01/24/23 Google to reduce bonuses for top executives, WSJ reports 01/24/23 Microsoft CEO felt company 'slow' to commercialize AI reserach, Information says 01/24/23 DOJ to file suit against Google over digital ad market dominance, Bloomberg says GE General Electric $80.72 / +0.925 (+1.16%) 01/03/23 GE to split off healthcare unit this week, WSJ reports 12/15/22 GE among companies studying Medtronic businesses, Bloomberg reports 11/30/22 Aerojet Rocketdyne deal pursued by GE, L3Harris, Reuters reports 11/30/22 Aerojet Rocketdyne deal pursued by GE, L3Harris, Reuters reports F Ford $12.74 / -0.065 (-0.51%) 01/24/23 Ford in discussions to sell German factory to BYD, WSJ reports 01/23/23 Union says Ford to slash up to 3,200 European jobs, Reuters reports 01/23/23 Ford planning massive layoffs overseas in favor of EV development, Electrek says 01/16/23 EVs made up 10% of all new cars sold last year, WSJ reports DHI D.R. Horton $97.04 / +1.365 (+1.43%) 11/12/22 Housing stocks have rallied, but could start falling again, Barron's says AMZN Amazon.com $96.35 / -1.16 (-1.19%) 01/20/23 Crystal Dynamics to accelerate end of 'Avengers' game development, Exputer says 01/19/23 Amazon cited for safety violations at three warehouses by OSHA, WSJ reports 01/18/23 Apple to expand smart-home lineup with new smart displays, Bloomberg says 01/18/23 Apple to expand smart-home lineup with new smart displays, Bloomberg says AMD AMD $74.72 / -1.82 (-2.38%) 01/11/23 TSMC receives 3nm chip orders from Broadcom, DigiTimes reports 01/04/23 China pauses chip industry investments as COVID resurges, Bloomberg reports 12/13/22 China files WTO complaint targeting prior U.S. chip sanctions, FT reports 12/01/22 TSMC plans to produce 4nm chips at Arizona plant, Bloomberg reports $ECON Economic Data / + 01/22/23 Fed sets course for milder interest-rate rise next month, WSJ says 11/04/22 Fed's Evans says smaller rate hikes make sense, Reuters reports 10/22/22 Fed set to raise rates by 0.75 point, discuss size of future hikes, WSJ says 10/10/22 JPMorgan CEO tells CNBC U.S. recession likely in 6 to 9 months XMTR VZ TRV TGTX SAVA RIVN PTON PD PARAA PARA MGA LYV LYFT LULU LMT JNJ GOOGL GE F DHI CBAY AMZN $ECON XMTR Xometry $31.16 / +1.94 (+6.64%) 01/24/23 What You Missed On Wall Street On Tuesday 01/24/23 What You Missed On Wall Street This Morning 01/13/23 Sell these stocks now, proven algorithm says 12/16/22 Sell these stocks now, proven algorithm says VZ Verizon $40.42 / +0.795 (+2.01%) 12/23/22 Buy/Sell: Wall Street's top 10 stock calls this week TRV Travelers $193.23 / +6.57 (+3.52%) 01/17/23 What You Missed On Wall Street On Tuesday 01/17/23 What You Missed On Wall Street This Morning TGTX TG Therapeutics $14.46 / +1.775 (+13.99%) 12/29/22 What You Missed On Wall Street On Thursday 12/29/22 What You Missed On Wall Street This Morning SAVA Cassava Sciences $29.44 / -7.01 (-19.23%) 11/18/22 Sell these stocks now, proven algorithm says 10/08/22 Short Report: Asana bearish position builds again after last-month's squeeze RIVN Rivian Automotive $18.05 / -0.03 (-0.17%) 01/23/23 What You Missed This Week in EVs and Clean Energy 01/17/23 What You Missed This Week in EVs and Clean Energy PTON Peloton $11.06 / -0.585 (-5.02%) 01/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/27/22 What You Missed On Wall Street On Tuesday PD PagerDuty $26.52 / -2.33 (-8.08%) 01/20/23 What You Missed On Wall Street On Friday 01/20/23 What You Missed On Wall Street This Morning PARAA Paramount $24.36 / -0.21 (-0.85%) 12/06/22 What You Missed On Wall Street On Tuesday 11/22/22 What You Missed On Wall Street On Tuesday 11/22/22 What You Missed On Wall Street This Morning PARA Paramount $20.83 / -0.33 (-1.56%) 01/22/23 Box Office Battle: ‘Avatar 2’ wins weekend, crosses $2B globally 01/16/23 Box Office Battle: ‘Avatar 2’ wins long weekend with $40.6M 01/08/23 Box Office Battle: ‘Avatar 2’ wins weekend with $45M, crosses $1.7B globally MGA Magna $60.75 / -4.71 (-7.20%) 12/05/22 What You Missed This Week in EVs and Clean Energy 11/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations LYV Live Nation $77.00 / +1.045 (+1.38%) 12/05/22 What You Missed On Wall Street This Morning 11/28/22 What You Missed On Wall Street On Monday LYFT Lyft $15.29 / -0.13 (-0.84%) 01/09/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations LULU Lululemon $311.35 / -4.73 (-1.50%) 01/09/23 What You Missed On Wall Street On Monday LMT Lockheed Martin $449.14 / +7.5 (+1.70%) 01/13/23 What You Missed On Wall Street On Friday JNJ Johnson & Johnson $168.30 / -0.065 (-0.04%) 01/07/23 Short Report: Bad News Bears continue to claw Silvergate, Futu Holdings GOOGL Alphabet $97.68 / -2.095 (-2.10%) 01/24/23 What Wall Street is saying about Microsoft ahead of earnings GE General Electric $80.72 / +0.925 (+1.16%) 01/24/23 Fly Intel: Pre-market Movers 01/04/23 What You Missed On Wall Street On Wednesday F Ford $12.74 / -0.065 (-0.51%) 01/23/23 What You Missed On Wall Street On Monday DHI D.R. Horton $97.04 / +1.365 (+1.43%) 11/09/22 Fly Intel: Pre-market Movers 10/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations CBAY CymaBay $7.63 / +1.025 (+15.52%) 12/05/22 Biotech Alert: Searches spiking for these stocks today AMZN Amazon.com $96.35 / -1.16 (-1.19%) 01/24/23 GoodRx under pressure as Amazon issues 'threat' with RxPass 01/19/23 What You Missed On Wall Street On Thursday $ECON Economic Data / + 01/18/23 What You Missed On Wall Street On Wednesday 12/15/22 What You Missed On Wall Street On Thursday 12/15/22 What You Missed On Wall Street This Morning 01/27/23 Consumer/E-Commerce 03/09/23 Biopharma/Biotech 02/01/23 NAFEM Show 2023 01/24/23 General Electric - GE 01/24/23 Verizon - VZ 01/24/23 Johnson & Johnson - JNJ 01/24/23 D.R. Horton - DHI 01/24/23 Travelers - TRV 01/24/23 3M - MMM 01/24/23 Lockheed Martin - LMT 01/31/23 AMD - AMD 02/01/23 Peloton - PTON 02/02/23 Alphabet - GOOG 02/02/23 Alphabet - GOOGL 02/02/23 Ford - F 02/02/23 Amazon.com - AMZN 02/09/23 Lyft - LYFT 02/10/23 Magna - MGA 02/16/23 Paramount - PARAA 02/16/23 Paramount - PARA 02/28/23 Rivian Automotive - RIVN 02/10/23 AMD 03/28/23 CymaBay VZ TRV TGTX TGT SPX SAVA RIVN PTON PARA MMM LYV LYFT LULU LMT JNJ GOOGL GOOG GE F DHI AMZN AMD VZ Verizon $40.42 / +0.795 (+2.01%) 12/15/22 Verizon call volume above normal and directionally bullish 12/15/22 Early notable gainers among liquid option names on December 15th 12/15/22 Unusually active option classes on open December 15th 10/21/22 Unusually active option classes on open October 21st TRV Travelers $193.23 / +6.57 (+3.52%) 10/19/22 Early notable gainers among liquid option names on October 19th TGTX TG Therapeutics $14.46 / +1.775 (+13.99%) 01/11/23 TG Therapeutics call volume above normal and directionally bullish 01/09/23 TG Therapeutics call volume above normal and directionally bullish 01/05/23 TG Therapeutics call volume above normal and directionally bullish 12/27/22 Unusually active option classes on open December 27th TGT Target $163.54 / -1.1 (-0.67%) 01/19/23 Target put volume heavy and directionally bearish 01/06/23 Early notable gainers among liquid option names on January 6th 01/06/23 Unusually active option classes on open January 6th 11/28/22 Early notable gainers among liquid option names on November 28th SPX S&P 500 / + 09/23/22 SPX Option volume on track for 3.25m contracts, 2nd highest on record SAVA Cassava Sciences $29.44 / -7.01 (-19.23%) 12/19/22 Cassava Sciences put volume heavy and directionally bearish 12/07/22 Cassava Sciences call volume above normal and directionally bullish 12/06/22 Cassava Sciences call volume above normal and directionally bullish 11/14/22 Cassava Sciences call volume above normal and directionally bullish RIVN Rivian Automotive $18.05 / -0.03 (-0.17%) 12/29/22 Unusually active option classes on open December 29th 12/28/22 Rivian call volume above normal and directionally bullish 11/09/22 Rivian options imply 10.8% move in share price post-earnings 10/10/22 Unusually active option classes on open October 10th PTON Peloton $11.06 / -0.585 (-5.02%) 01/24/23 Peloton Interactive put volume heavy and directionally bearish 01/06/23 Peloton Interactive call volume above normal and directionally bullish 12/15/22 Largest borrow rate increases among liquid names 12/07/22 Largest borrow rate increases among liquid names PARA Paramount $20.83 / -0.33 (-1.56%) 01/23/23 Paramount Global call volume above normal and directionally bullish 01/04/23 Heavy put volume in Paramount Global 01/03/23 Early notable gainers among liquid option names on January 3rd 12/27/22 Paramount Global call volume above normal and directionally bullish MMM 3M $115.00 / -7.67 (-6.25%) 09/01/22 Early notable gainers among liquid option names on September 1st 09/01/22 Notable open interest changes for September 1st 08/31/22 Notable open interest changes for August 31st 08/30/22 Record option volume and open interest in 3M as traders set up for spinoff LYV Live Nation $77.00 / +1.045 (+1.38%) 12/12/22 Live Nation put volume heavy and directionally bearish 11/29/22 Early notable gainers among liquid option names on November 29th 11/21/22 Early notable gainers among liquid option names on November 21st LYFT Lyft $15.29 / -0.13 (-0.84%) 01/11/23 Lyft call volume above normal and directionally bullish 01/05/23 Unusual call flow in option market yesterday 01/04/23 Call volume gets a lift in Lyft 12/20/22 Lyft put volume heavy and directionally bearish LULU Lululemon $311.35 / -4.73 (-1.50%) 01/04/23 Lululemon put volume heavy and directionally bearish 12/21/22 Unusually active option classes on open December 21st 12/12/22 Unusually active option classes on open December 12th LMT Lockheed Martin $449.14 / +7.5 (+1.70%) 11/17/22 Early notable gainers among liquid option names on November 17th 10/18/22 Unusually active option classes on open October 18th 08/02/22 Lockheed Martin call volume above normal and directionally bullish JNJ Johnson & Johnson $168.30 / -0.065 (-0.04%) 01/20/23 Johnson & Johnson put buyer realizes 33% same-day gains 01/11/23 Unusually active option classes on open January 11th 12/22/22 Johnson & Johnson put volume heavy and directionally bearish GOOGL Alphabet $97.68 / -2.095 (-2.10%) 01/20/23 Early notable gainers among liquid option names on January 20th 01/20/23 Unusually active option classes on open January 20th 12/05/22 Alphabet Class A call volume above normal and directionally bullish 11/04/22 Notable open interest changes for November 4th GOOG Alphabet $99.20 / -1.99 (-1.97%) 12/14/22 Alphabet put buyer realizes 126% same-day gains 11/02/22 Alphabet put buyer realizes 98% same-day gains 10/25/22 Alphabet options imply 5.4% move in share price post-earnings GE General Electric $80.72 / +0.925 (+1.16%) 01/24/23 Unusually active option classes on open January 24th 01/05/23 Notable open interest changes for January 5th 01/04/23 General Electric call volume above normal and directionally bullish 01/03/23 General Electric put volume heavy and directionally bearish F Ford $12.74 / -0.065 (-0.51%) 01/17/23 Ford put volume heavy and directionally bearish 12/30/22 Notable open interest changes for December 30th 12/19/22 Unusually active option classes on open December 19th 11/11/22 Unusually active option classes on open November 11th DHI D.R. Horton $97.04 / +1.365 (+1.43%) 01/19/23 D R Horton put volume heavy and directionally bearish 11/09/22 Early notable gainers among liquid option names on November 9th 10/31/22 D R Horton put volume heavy and directionally bearish 10/19/22 D R Horton put volume heavy and directionally bearish AMZN Amazon.com $96.35 / -1.16 (-1.19%) 01/24/23 Notable open interest changes for January 24th 01/23/23 Notable open interest changes for January 23rd 01/20/23 Notable open interest changes for January 20th 01/17/23 Notable open interest changes for January 17th AMD AMD $74.72 / -1.82 (-2.38%) 01/23/23 Early notable gainers among liquid option names on January 23rd 01/09/23 Early notable gainers among liquid option names on January 9th 01/09/23 Advanced Micro call buyer realizes 99% same-day gains SPY SPY SPDR S&P 500 ETF Trust $400.15 / -0.44 (-0.11%) 01/24/23 SPDR S&P 500 ETF Trust: Pivot points 01/23/23 SPDR S&P 500 ETF Trust: Pivot points 01/20/23 SPDR S&P 500 ETF Trust: Pivot points 01/19/23 SPDR S&P 500 ETF Trust: Pivot points

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial